KDIGO Issues Amendments to 2024 ANCA Vasculitis Guideline |
|
The KDIGO 2024 ANCA Vasculitis Guideline is a focused update of the ANCA Vasculitis chapter of The KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. The guideline was published in the March 2024 issue of Supplement to Kidney International, with an Executive Summary in the main pages of the journal. The guideline was co-chaired by Brad Rovin, MD (United States) and Jürgen Floege, MD (Germany), who co-chaired the 2021 Glomerular Diseases Guideline and are co-chairing additional chapter updates.
The guideline provides updated recommendations and practice points based on evidence from randomized controlled trials published since July 2022. This includes new evidence on using lower doses of corticosteroids and addresses the role of avacopan as an alternative to glucocorticoids. The guideline also discusses therapies such as plasma exchange for use in patients with advanced kidney disease.
|
|
KDIGO Holds Controversies Conference on APOL1 Kidney Disease |
|
KDIGO held a Controversies Conference in Accra, Ghana, in April to address key controversies and knowledge gaps surrounding APOL1 kidney disease. The conference, co-chaired by Akinlolu Ojo, MD (United States), and Ifeoma Ulasi, MD (Nigeria), brought together leading experts in apolipoprotein L1 (APOL1)-related pathologies, as well as patients and caregivers.
In people of African ancestry, specific mutations in the APOL1 gene are strongly associated with a high risk of chronic kidney disease (CKD). Among African Americans, approximately 25% with two APOL1 risk alleles develop CKD, and two APOL1 risk alleles are present in 40-60% with primary focal and segmental glomerulosclerosis. More than 100 million sub-Saharan Africans may have a lifetime increased risk of CKD or accelerated progression due to having two APOL1 risk alleles, making the burden of APOL1 kidney disease in sub-Saharan Africa catastrophically high.
"This interactive conference allowed us to comprehensively review the latest research and identify crucial areas where more understanding is needed about how APOL1 genetic variants lead to kidney disease, especially in populations of West African ancestry," said Dr. Ojo. "The output will guide future research directions and clinical management of this devastating condition."
The conference addressed a wide range of topics, including the pathophysiology and mechanisms of APOL1 kidney disease; epidemiology and risk factors for APOL1 kidney disease; characteristics and manifestations of APOL1 kidney disease; potential lifestyle and medical interventions to slow disease progression; and utility and implications of genetic screening for APOL1 kidney disease (e.g., impact on living donor considerations, psychological well-being, financial implications). The meeting attendees will generate a conference report to inform the global medical community on screening, diagnosis, therapeutic management, and priority research areas.
Dr. Ulasi added, "By tackling complex issues through focused sessions and discussions, we made important progress towards a unified terminology and approach to studying and treating APOL1 kidney disease. We are especially grateful for the patients and caregivers' presence at this conference, which was especially impactful in helping clinicians understand all aspects of this complex disease. We hope the conference report will help guide future research and improve outcomes for people with APOL1 kidney disease."
|
|
KDIGO 2024 Guideline on ANCA-Associated Vasculitis Webinar Series Webinar One: Update on Management and Treatment
Wedesday, May 15, 8:00 AM EDT, 2:00 PM CEST
New trial data have emerged resulting in the approval of novel therapeutic agents in the management of AAV. With the increased availability of treatment options, there is considerable complexity in determining the optimal approach given the rarity of the disease.
To this end, this webinar aims to review the latest KDIGO guidance, highlight the key guideline takeaways, and illustrate the appropriate application of recommendations and practice points through the use of real-world clinical vignettes. We hope to see you there!
|
|
KDIGO 2024 Guideline on ANCA-Associated Vasculitis Webinar Series Webinar 2: Reading Between the Lines
Thursday, May 30 at 11:00 AM EDT, 5:00 PM CEST
In KDIGO 2024 Guideline on ANCA-Associated Vasculitis: Reading Between the Lines, guideline Co-Chair, Brad Rovin, MD (United States), and Geetha Duvuru, MD (United States) review the latest KDIGO guidance through the use of case-based studies, including discussion on indications for plasma exchange and avacopan, to showcase challenging patient scenarios and illustrate the optimal application of guideline recommendations and practice points.
Topics to be addressed in this webinar include:
• Optimal treatment in patients with refractory disease
• Appropriate management in patients with relapsing disease
• Ideal approach in patients with organ/life-threatening disease
• Management of AAV in kidney transplant population
Case studies will involve discussions on the optimal indications for plasma exchange and avacopan, given the interest on the controversial issue of the former and the nascent familiarity of the latter. Learn more and register.
|
|
Personalizing Our Approach: A Focus on Managing the Non-Diabetic Patient in CKD
Wednesday, May 22 at 14:30 BST, 9:30 EDT
In this webinar, KDIGO CKD Guideline Work Group Members Rasheeda Hall, MD (United States) and William Herrington, MD (United Kingdom) will guide attendees through an interactive case study. The webinar includes a live Q&A, so bring your questions for the experts!
Don't miss the last webinar in this exciting series. The first four webinars are now available on demand. Watch the webinar series.
|
|
KDIGO at the 61st ERA Congress Stockholm & Virtual
May 23-26, 2024
Are you attending the ERA 2024 Congress in Stockholm, Sweden? Make sure to stop by the KDIGO booth (A310) and attend the KDIGO symposium and sessions at this year's congress.
The symposium KDIGO Update - The Impact of Viral Infections in Patients with Renal Diseases and the Role of Vaccination in Kidney Care, features series of case studies presented by global experts, followed by a panel discussion and Q&A session. Presentations include, "Viral Encounters - Understanding the Burden of on Kidney Health," "Navigating the Risks for Patients with CKD and GD," "Overcoming Barriers for Patients on Dialysis," and "Addressing Challenges for Patients with Kidney Transplant." We hope to see you at this dynamic symposium. The symposium will take place on May 23 at 12:15 CEST in Stockholmsmässan Room A5.
|
|
The session KDIGO 2024 Guideline on Lupus Nephritis (LN): A Roundtable Discussion will take place on Friday, May 24, at 13:45 CEST in Stockholmsmässan Room A6. The session is co-chaired by KDIGO LN Guideline Co-Chair Brad Rovin, MD (United States) and LN Guideline Work Group Member Vladimir Tesar, MD (Czechia), with presentations by LN Guideline Work Group Members Juan Manuel Mejía Vilet, MD (Mexico) and Isabelle Ayoub, MD (United States).
The session also features a patient perspective on living with lupus by Jeanette Andersen (Denmark). Hear the latest science and updates from the recently released guideline and this exciting session.
KDIGO will hold the session KDIGO Update - ADPKD Guideline 2024 on Sunday, May 26 at 8:30 in the Plenary Hall. The session features KDIGO ADPKD Guideline Co-Chairs Olivier Devuyst, MD (Switzerland) and Vicente Torres, MD (United States), with ADPKD Guideline Work Group Members, Roser Torra, MD (Spain). and Djalila Mekahli, MD (Belgium). Don't miss the chance to hear a preview of the KDIGO ADPKD Guideline, which will be published later this year.
|
|
Optimising RAASi Management in Cardiorenal Patients: An Expert Roundtable
On Demand Webinar
In this discussion, these expert faculty consider approaches to optimal RAASi dosing and strategies to improve patient outcomes. The programme integrates data-driven insights, established guidelines, and expert consensus, offering participants a holistic understanding of RAASi management.
A case study highlights how to overcome barriers to optimal guideline-directed medical therapy. The panel discussion bridges theory and real-world application, providing you with actionable tools to implement optimal practices in your daily clinical pursuits. Watch the webinar.
|
|
An Expert Approach to Cardio-Renal Protection in CKD: A Case Based Discussion Parts 1 and 2
On Demand Webinar Series
This two-part program, produced with Radcliffe Cardiology, considers the guideline-directed approach to chronic kidney disease (CKD) and how SGLT-2 inhibitors can be used to maximal effect. The webinars are chaired by Professor James Burton, MD (United Kingdom), with expert insight from world-renowned faculty Professor David Wheeler, MD (United Kingdom), Professor Navdeep Tangri, MD (Canada), and Professor Carol Pollock, MD (Australia).
In Part 1 of this dynamic series, the expert panel unravels the complexities of CKD care in the context of a real-world patient case. Part 2 offers a forensic analysis of current practices, revisiting the patient case from Part 1 in reflection of expected guideline updates. The panel provides evidence-based strategies for initiating pharmacological therapies that transcend the theoretical and become actionable in everyday practice.
|
|
Exploring Developments in IgAN and FSGS
On Demand CME Webinar
Available in English and French
IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) stand as two of the most prevalent primary glomerular diseases, impacting millions worldwide. These conditions can lead to kidney failure, necessitating dialysis or transplantation.
In Exploring Developments in IgAN and FSGS renowned experts Richard Lafayette, MD (United States) and Howard Trachtman, MD (United States) delve into the transformative impact of recent clinical trial outcomes on the treatment landscape for patients with IgAN and FSGS. The webinar, developed by Medtelligence, is also available in French. Learn how proteinuria remission and a significantly reduced risk of disease progression can be achieved in your patients battling IgAN and FSGS. Watch the webinar in English or French.
|
|
Incorporating Targeted Therapies in Treatment Planning for AAV
On Demand CME Webinar
Available in English and Spanish
ANCA-associated vasculitis (AAV) is a complex autoimmune disease. This condition can lead to life-threatening complications that primarily affect kidney function due to necrotizing glomerulonephritis. In Incorporating Targeted Therapies in Treatment Planning for AAV, Bernhard Hellmich, MD (Germany) and David Jayne, MD (United Kingdom) discuss how to incorporate targeted therapies when managing AAV.
This webinar, developed by Medtelligence and available in Spanish, is designed to meet the educational needs of nephrologists and rheumatologists. After participating in this educational activity, participants should be better able to identify the role of the alternative complement pathway in the pathogenesis of AAV, contrast the efficacy and safety of induction and maintenance therapies in managing patients with AAV, and identify patients who may benefit from C5a inhibitors. Watch the webinar in English or in Spanish.
|
|
About KDIGO
KDIGO is a Belgian foundation committed to developing and implementing nephrology guidelines that improve outcomes for people with kidney disease on a global basis. KDIGO is independent, volunteer-led, self-managed, and accountable to the public and the people it serves. Learn more.
|
|
|
|
|
|
|
